Cyclo Therapeutics, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the last patient has undergone the final assessment in its...
Bellwyck Pharma Services Brings Strong Presence in Key Markets, Increasing Breadth of PCI’s Global Network PHILADELPHIA — PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, today announced the acquisition...
BURLINGTON, Mass. & OXFORD, England–(BUSINESS WIRE)–Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced upcoming presentations of additional analyses from the FALCON clinical trial (NCT02578940) of...
Orphazyme A/S Also Completed a Major New Capital Raise of $110 Million to Cover its Expansion CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement [11-February-2020] LOS ANGELES, Feb. 11,...
Elicio Therapeutics, a next generation immuno-oncology company, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology...
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences GroupGroup, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer...
Email
Text